Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3467-3474

  Florell, Scott R ^a   Martinchick, James F ^a   Holden, Joseph A ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Non Hodgkin's lymphoma; Purification; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DODECYL SULFATE SODIUM; HYDROXYAPATITE;

AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA CLEAVAGE; DNA SUPERCOILING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MOLECULAR WEIGHT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SPLEEN;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA, SUPERHELICAL; ELECTROPHORESIS, AGAR GEL; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM PROTEINS; SPLENIC NEOPLASMS;

EID: 0030485714     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sinha BK: Topoisomerase inhibitors-A review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995.
2. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S and Ota K: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912, 1990.
3. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN and Hong WK: Phase II study of topotecan in patients with advanced nonsmall-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513, 1996.
4. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou T, Sun N, Pulliam S and Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996.
5. Watt PM, and Hickson ID: Struture and function of type II DNA topoisomerases. Biochem J 303: 681-695, 1994.
6. Gilmour DS and Elgin SCR: Localization of specific topoisomerase interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin. Mol Cell Biol 7: 141-148, 1987.
7. Kjeldsen E, Svejstrup JQ, Gromova II, Alsner J and Westergaard O: Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase 1. J Mol Biol 228: 1025-1030, 1992.
8. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260; 14873-14876, 1985,
9. Hsaing Y-H, Lihou MG and Liu LF: Mechanism of cell killing by camptothecin: arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes. Cancer Res 49: 5077-5082, 1989.
10. Madden KR and Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 52: 525-532, 1992.
11. Bjornsti M-A, Benedetti P, Viglianti GA, and Wang JC: Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49: 6318-6323, 1989.
12. Mcleod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AGJ, Kaye SB, Brown R and Keith WN: Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer 59; 607-611, 1994.
13. van der Zee AGJ, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG and de Vries EGE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991.
14. van der Zee AGJ, de Jong S, Keith WN, Hollema H, Boonstra H and de Vries EGE: Quantitative and qualitative aspects of topoisomerase I and Ilalpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749-755, 1994.
15. Husain I, Mohler JL, Seigler HF and Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994.
16. Bronstein IB, Vorobyev SG, Timofeev A, Jolles CJ, Alder SL and Holden JA: Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8: 17-25, 1996.
17. Durban E, Goodenough M, Mills J and Busch H: Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells. EMBO J 4: 2921-2926, 1985.
18. Kaiserman HB, Ingebritsen TS, Benbow RM: Regulation of Xenopus laevis DNA topoisomerase I activity by phosphorylation in vitro. Biochemistry 27: 3216-3222, 1988.
19. Kasid UN, Halligan B, Liu LF, Dritschilo A and Smulson M: Poly (ADPribose)-mediated post-translational modification of chromatinassociated human topoisomerase I. J Biol Chem 264: 18687-18692, 1989.
20. Holden JA, Rolfson DH and Wittwer CT: Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 29: 2127-2134, 1990.
21. Holden JA, Rolfson DH and Low RL: DNA topoisomerase I from human placenta. Biochim Biophys Acta 1049: 303-310, 1990.
22. Juenke JM and Holden JA: The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1216: 191-196, 1993.
23. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254, 1976.
24. Liu LF and Miller KG: Eukaryotic DNA topoisomerases: two forms of type I topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci (USA) 78: 3487-3491, 1981.
25. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469, 1989.
26. Badaracco G, Plevani P, Ruyechan WT, Chang LMS: Purification and characterization of yeast topoisomerase I. J Biol Chem 258: 2022-2026, 1983.
27. Vosberg H-P, Grossman LI and Vinograd J: Isolation and partial characterisation of the relaxation protein from nuclei of cultured mouse and human cells. Eur J Biochem 55: 79-93, 1975.
28. Samuels DS, Shimizu Y and Shimizu N: Protein kinase C phosphorylates DNA topoisomerase I. FEBS Letters 259: 57-60, 1989.
29. Coderoni S, Paparelli M and Gianfranceschi GL: Phosphorylation sites for type N II protein kinase in DNA-topoisomerase I from call thymus. Int J Biochem 22: 737-746, 1990.
30. Holden JA, Perkins SL, Snow GW and Kjeldsberg CR: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Amer J Clin Path 104: 54-59, 1995.
31. Attardi DG, De Paolis A and Tocchini-Valentini GP: Purification and characterization of Xenopus laevis type I topoisomerase. J Biol Chem 256: 3654-3661, 1981.
32. Stewart L, Ireton GC, Parker LH, Madden KR and Champoux JJ: Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 277: 7593-7609, 1996.
33. Kornberg A: Structure and functions of DNA. DNA Replication, W.H. Freeman and Company, San Francisco, pp1-38, 1980.
34. Wang JC: Superhelical DNA. Trends in Biochem. Sci 5: 219-221, 1980.
35. Holden JA and Low RL: Characterization of a potent catenation activity of Hela cell nuclei. J Biol Chem 27: 14491-14497, 1985.
36. Shuman S, Golder M and Moss B: Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli. J Biol Chem 263: 16401-16407, 1988.